Dongwha Pharm Receives Approval for Phase 2 Clinical Trial of COVID-19 Treatment
[Asia Economy Reporter Cho Hyun-ui] Dong Wha Pharm announced on the 24th that the Ministry of Food and Drug Safety has approved the Phase 2 clinical trial plan for the novel coronavirus disease (COVID-19) treatment 'DW2008S'.
This clinical trial will evaluate the efficacy and safety of DW2008S, which is being developed as an asthma treatment, in patients with moderate COVID-19.
DW2008S demonstrated safety and tolerability in clinical trials conducted on healthy individuals during its development as an asthma treatment, and a Phase 2 clinical trial for asthma treatment is currently underway.
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- "Concerns Over Expanded Travel Rule"... FIU Holds Closed Meeting with Virtual Asset Industry on Enforcement Decree of the Act on Specified Financial Transaction Information
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Dong Wha Pharm stated, "In addition to DW2008S, we are conducting two studies under the support of the Ministry of Science and ICT government project: a GLP toxicity test for non-clinical research using the single active ingredient of DW2008S, and a new drug candidate discovery study using novel derivative substances."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
